Ann Subota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ann Subota has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Samuel Wiebe
Department of Clinical Neurosciences, Cumming School of Medicine University of Calgary Calgary Alberta Canada
5 shared publications Mandavi Kashyap
3 shared publicationsColin B. Josephson
Department of Clinical Neurosciences, Cumming School of Medicine University of Calgary Calgary Alberta Canada
2 shared publications- Colin Bruce Josephson
Department of Clinical Neurosciences, Cumming School of Medicine University of Calgary Calgary Alberta Canada
2 shared publications - Nathalie Jetté
Department of Clinical Neurosciences, Cumming School of Medicine University of Calgary Calgary Alberta Canada
2 shared publications - Paolo Federico
Department of Clinical Neurosciences, Cumming School of Medicine University of Calgary Calgary Alberta Canada
2 shared publications
Latest Publications
- Open Access
Clinical features of the postictal state in adults with epilepsy: A cross‐sectional survey
Objective: Persons with epilepsy may experience many postictal symptoms after a seizure, which can significantly impact quality of life. We aimed to determine the frequency, duration, and severity of postictal symptoms to better characterize the postictal period. Methods: Our cross‐sectional questionnaire was adapted from a prior pediatric postictal survey. Face and content validity were evaluated by epilepsy experts and patients from the Calgary Epilepsy Program (CEP). The survey was pilot tested and modified, consisting of 14 physical, cognitive, and psychiatric postictal signs and symptoms. Consecutive CEP adults who had agreed to participate in research and experienced a seizure in the prior 2 years were approached. CEP clinical data were used to supplement survey data. Frequency of factors alleviating and exacerbating postictal symptoms were examined. Spearman's rho was used to explore associations between survey and CEP registry data with statistical significance at ≤ 0.05. Results: Of 351 patients approached, 313 agreed to participate (89%). Fourteen were lost after consent was obtained, and 15 were excluded (incomplete surveys, missing registry data, not having epilepsy). Of the 298 final participants, 54% were female, mean age was 40 years (SD = 15.6), and 95% (282/298) experienced at least one postictal symptom. The three most frequent postictal symptoms were fatigue, sleepiness, or tiredness (84%), confusion or difficulty thinking clearly (75%), and memory problems (69%). For eight of 14 captured postictal symptoms, the most frequently reported symptom duration was <5 min. Mean postictal symptom burden score was correlated with patient reported quality of life and epilepsy‐related disability measures. Sleep or rest, medication, and food or drinks were the most common alleviating factors. Lack of rest or sleep, and stress most often exacerbated postictal symptoms. Significance: This work contributes toward a better understanding of the postictal period and informs the development of future interventions to minimize the impact of the postictal period in epilepsy.
Open AccessClinical features of the postictal state in adults with epilepsy: A cross‐sectional survey
Objective: Persons with epilepsy may experience many postictal symptoms after a seizure, which can significantly impact quality of life. We aimed to determine the frequency, duration, and severity of postictal symptoms to better characterize the postictal period. Methods: Our cross‐sectional questionnaire was adapted from a prior pediatric postictal survey. Face and content validity were evaluated by epilepsy experts and patients from the Calgary Epilepsy Program (CEP). The survey was pilot tested and modified, consisting of 14 physical, cognitive, and psychiatric postictal signs and symptoms. Consecutive CEP adults who had agreed to participate in research and experienced a seizure in the prior 2 years were approached. CEP clinical data were used to supplement survey data. Frequency of factors alleviating and exacerbating postictal symptoms were examined. Spearman's rho was used to explore associations between survey and CEP registry data with statistical significance at ≤ 0.05. Results: Of 351 patients approached, 313 agreed to participate (89%). Fourteen were lost after consent was obtained, and 15 were excluded (incomplete surveys, missing registry data, not having epilepsy). Of the 298 final participants, 54% were female, mean age was 40 years (SD = 15.6), and 95% (282/298) experienced at least one postictal symptom. The three most frequent postictal symptoms were fatigue, sleepiness, or tiredness (84%), confusion or difficulty thinking clearly (75%), and memory problems (69%). For eight of 14 captured postictal symptoms, the most frequently reported symptom duration was <5 min. Mean postictal symptom burden score was correlated with patient reported quality of life and epilepsy‐related disability measures. Sleep or rest, medication, and food or drinks were the most common alleviating factors. Lack of rest or sleep, and stress most often exacerbated postictal symptoms. Significance: This work contributes toward a better understanding of the postictal period and informs the development of future interventions to minimize the impact of the postictal period in epilepsy.
- Open Access
- 18 August 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 199
Interpreting effect size of patient-reported outcome measures in epilepsy: toward empirical benchmarks
- 18 August 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 199
Open AccessInterpreting effect size of patient-reported outcome measures in epilepsy: toward empirical benchmarks
- 10 April 2026
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1
Reviewer Comment on Momen et al. “Demographic and Clinical Characteristics of Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults”
- 10 April 2026
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1
Reviewer Comment on Momen et al. “Demographic and Clinical Characteristics of Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults”
- Open Access
Are single‐item global rating scales the same, better, or worse than multi‐item scales in epilepsy: A scoping review and meta‐analysis
Objective: To examine the performance of single‐item global ratings (SIGRs) and multi‐item scales (MISs) in epilepsy research, and assess the influence of diverse constructs, study designs, and statistical methods. Methods: Systematic scoping review following Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) and Joanna Briggs Institute guidelines. MEDLINE, Embase, PsycINFO, CINAHL, and the Cochrane Register of Controlled Trials were searched from 1980 onward. English‐language articles including ≥30 persons with epilepsy and using at least one SIGR and one MIS were analyzed. Citation screening at all levels was done independently by two reviewers; data extraction was standardized. We analyzed individual measurements of effect magnitude for SIGRs and MISs. For meta‐analyses, correlation‐related metrics were transformed to Pearson r and Fisher z transformed, and effect‐size metrics were converted to Cohen's d with Hedges g correction. Multilevel meta‐analyses were used to account for data heterogeneity and clustering of effect sizes within studies, and to assess the influence of predefined moderators. Publication bias was assessed with standard methods. Results: A total of 18 267 citations were identified, and 58 studies were included. Effect magnitude was medium to large across measurements, and it was slightly larger for MISs than for SIGRs, both for correlations and effect sizes (difference = .04, p < .001). Overall, SIGRs and MISs were comparable, and statistically significant differences did not cross effect thresholds (from small to medium or medium to large). Correlations and effect sizes for SIGRs and MISs were lowest in studies involving children and when assessing change; and for SIGRs when Global Clinical Impression (GCI) formats were used. Significance: SIGRs are likely comparable to MISs across multiple study and statistical contexts. However, in certain clinical scenarios, MISs will outperform SIGRs and vice versa. Researchers should carefully consider whether SIGRs, MISs, or a combination is most appropriate to answer the research question.
Open AccessAre single‐item global rating scales the same, better, or worse than multi‐item scales in epilepsy: A scoping review and meta‐analysis
Objective: To examine the performance of single‐item global ratings (SIGRs) and multi‐item scales (MISs) in epilepsy research, and assess the influence of diverse constructs, study designs, and statistical methods. Methods: Systematic scoping review following Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) and Joanna Briggs Institute guidelines. MEDLINE, Embase, PsycINFO, CINAHL, and the Cochrane Register of Controlled Trials were searched from 1980 onward. English‐language articles including ≥30 persons with epilepsy and using at least one SIGR and one MIS were analyzed. Citation screening at all levels was done independently by two reviewers; data extraction was standardized. We analyzed individual measurements of effect magnitude for SIGRs and MISs. For meta‐analyses, correlation‐related metrics were transformed to Pearson r and Fisher z transformed, and effect‐size metrics were converted to Cohen's d with Hedges g correction. Multilevel meta‐analyses were used to account for data heterogeneity and clustering of effect sizes within studies, and to assess the influence of predefined moderators. Publication bias was assessed with standard methods. Results: A total of 18 267 citations were identified, and 58 studies were included. Effect magnitude was medium to large across measurements, and it was slightly larger for MISs than for SIGRs, both for correlations and effect sizes (difference = .04, p < .001). Overall, SIGRs and MISs were comparable, and statistically significant differences did not cross effect thresholds (from small to medium or medium to large). Correlations and effect sizes for SIGRs and MISs were lowest in studies involving children and when assessing change; and for SIGRs when Global Clinical Impression (GCI) formats were used. Significance: SIGRs are likely comparable to MISs across multiple study and statistical contexts. However, in certain clinical scenarios, MISs will outperform SIGRs and vice versa. Researchers should carefully consider whether SIGRs, MISs, or a combination is most appropriate to answer the research question.
- 9 December 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (5) , 456-463
Non-motor symptoms in Parkinson’s disease: a practical approach
Non-motor symptoms of Parkinson’s disease (PD) drive disability, reduce quality of life and increase healthcare resource use. Yet, they are often under-recognised in time-limited clinics. We outline an evidence-informed approach for everyday neurology. We propose brief previsit process followed by in-visit prioritisation of one or two high-impact symptoms and simple education/resources for the rest. Psychosis requires clinicians to address triggers, simplify dopaminergic therapy and use PD-safe antipsychotics when required. Mood and anxiety benefit from optimised dopaminergic regimens, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors, counselling, exercise and online cognitive-behavioural programmes. Cognitive impairment warrants regular screening and medication review; cholinesterase inhibitors are indicated for dementia. Sleep management includes treating contributing factors, hygiene measures and cautious hypnotic use. Pain and autonomic dysfunction require pragmatic, stepwise strategies tailored to real-world practice. We include special considerations for atypical Parkinsonism and caregiver needs. Integrating these steps into routine visits improves safety, function and patient–carer well-being.
- 9 December 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (5) , 456-463
Non-motor symptoms in Parkinson’s disease: a practical approach
Non-motor symptoms of Parkinson’s disease (PD) drive disability, reduce quality of life and increase healthcare resource use. Yet, they are often under-recognised in time-limited clinics. We outline an evidence-informed approach for everyday neurology. We propose brief previsit process followed by in-visit prioritisation of one or two high-impact symptoms and simple education/resources for the rest. Psychosis requires clinicians to address triggers, simplify dopaminergic therapy and use PD-safe antipsychotics when required. Mood and anxiety benefit from optimised dopaminergic regimens, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors, counselling, exercise and online cognitive-behavioural programmes. Cognitive impairment warrants regular screening and medication review; cholinesterase inhibitors are indicated for dementia. Sleep management includes treating contributing factors, hygiene measures and cautious hypnotic use. Pain and autonomic dysfunction require pragmatic, stepwise strategies tailored to real-world practice. We include special considerations for atypical Parkinsonism and caregiver needs. Integrating these steps into routine visits improves safety, function and patient–carer well-being.
- Open Access
Scoping review of single‐item global rating scales utilized in epilepsy research: Patterns of use, challenges, and recommendations
SIGRs (single‐item global ratings) are gaining popularity among clinicians and health researchers as efficient tools to assess patient‐reported outcomes. There has been no systematic assessment of domains explored, methodological aspects, and validation efforts of SIGRs in epilepsy. We aimed to critically appraise and provide recommendations on the use and reporting of SIGRs in epilepsy research. We performed a systematic scoping review using the Joanna Briggs Institute's recommendations. The Preferred Reporting Items for Systematic Reviews and Meta‐analysis (PRISMA) method was used to search five electronic databases (MEDLINE, Embase, PsycINFO, CINAHL, and Cochrane Register of Controlled Trials) from 1980 to present day. We included English‐language s tudies utilizing SIGRs that assessed health aspects (concept) in people with epilepsy of all ages (participants), in all settings (context), containing ≥30 patients, and using SIGRs with continuous or categorical responses in any study design. Abstract and full‐text review was conducted independently by two reviewers; disagreements were resolved through consensus. Standardized data abstraction was used. Of 16 417 citations, we included 289 studies, involving 114 584 patients who underwent 747 unique measurements using SIGRs. Use increased over time; 30% were published in the last 4 years, and 51% used 1 SIGR (range 1–23 SIGRs). Commonly assessed domains were overall health (24.2%) and seizure‐related aspects (23.5%), whereas 37% measured perceived change. Most studies used SIGRs descriptively (80.1%). Numerous SIGR formats were used (most commonly Likert‐like, 73.3%). Ad hoc SIGRs without validation occurred frequently (45.6%). Stem questions were absent in 9.5% of measures, and only 6.5% reported SIGR measurement properties. SIGRs are widely used and increasingly prevalent in epilepsy research to assess diverse domains across various formats. However, many SIGRs suffer from poor reporting and methodological limitations. We provide a comprehensive catalog of SIGRs and offer recommendations to improve their use in research and clinical practice.
Open AccessScoping review of single‐item global rating scales utilized in epilepsy research: Patterns of use, challenges, and recommendations
SIGRs (single‐item global ratings) are gaining popularity among clinicians and health researchers as efficient tools to assess patient‐reported outcomes. There has been no systematic assessment of domains explored, methodological aspects, and validation efforts of SIGRs in epilepsy. We aimed to critically appraise and provide recommendations on the use and reporting of SIGRs in epilepsy research. We performed a systematic scoping review using the Joanna Briggs Institute's recommendations. The Preferred Reporting Items for Systematic Reviews and Meta‐analysis (PRISMA) method was used to search five electronic databases (MEDLINE, Embase, PsycINFO, CINAHL, and Cochrane Register of Controlled Trials) from 1980 to present day. We included English‐language s tudies utilizing SIGRs that assessed health aspects (concept) in people with epilepsy of all ages (participants), in all settings (context), containing ≥30 patients, and using SIGRs with continuous or categorical responses in any study design. Abstract and full‐text review was conducted independently by two reviewers; disagreements were resolved through consensus. Standardized data abstraction was used. Of 16 417 citations, we included 289 studies, involving 114 584 patients who underwent 747 unique measurements using SIGRs. Use increased over time; 30% were published in the last 4 years, and 51% used 1 SIGR (range 1–23 SIGRs). Commonly assessed domains were overall health (24.2%) and seizure‐related aspects (23.5%), whereas 37% measured perceived change. Most studies used SIGRs descriptively (80.1%). Numerous SIGR formats were used (most commonly Likert‐like, 73.3%). Ad hoc SIGRs without validation occurred frequently (45.6%). Stem questions were absent in 9.5% of measures, and only 6.5% reported SIGR measurement properties. SIGRs are widely used and increasingly prevalent in epilepsy research to assess diverse domains across various formats. However, many SIGRs suffer from poor reporting and methodological limitations. We provide a comprehensive catalog of SIGRs and offer recommendations to improve their use in research and clinical practice.
- Top Cited PapersOpen Access
Treatment of seizures in the neonate: Guidelines and consensus‐based recommendations—Special report from the ILAE Task Force on Neonatal Seizures
Seizures are common in neonates, but there is substantial management variability. The Neonatal Task Force of the International League Against Epilepsy (ILAE) developed evidence‐based recommendations about antiseizure medication (ASM) management in neonates in accordance with ILAE standards. Six priority questions were formulated, a systematic literature review and meta‐analysis were performed, and results were reported following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) 2020 standards. Bias was evaluated using the Cochrane tool and risk of Bias in non‐randomised studies ‐ of interventions (ROBINS‐I), and quality of evidence was evaluated using grading of recommendations, assessment, development and evaluation (GRADE). If insufficient evidence was available, then expert opinion was sought using Delphi consensus methodology. The strength of recommendations was defined according to the ILAE Clinical Practice Guidelines development tool. There were six main recommendations. First, phenobarbital should be the first‐line ASM (evidence‐based recommendation) regardless of etiology (expert agreement), unless channelopathy is likely the cause for seizures (e.g., due to family history), in which case phenytoin or carbamazepine should be used. Second, among neonates with seizures not responding to first‐line ASM, phenytoin, levetiracetam, midazolam, or lidocaine may be used as a second‐line ASM (expert agreement). In neonates with cardiac disorders, levetiracetam may be the preferred second‐line ASM (expert agreement). Third, following cessation of acute provoked seizures without evidence for neonatal‐onset epilepsy, ASMs should be discontinued before discharge home, regardless of magnetic resonance imaging or electroencephalographic findings (expert agreement). Fourth, therapeutic hypothermia may reduce seizure burden in neonates with hypoxic–ischemic encephalopathy (evidence‐based recommendation). Fifth, treating neonatal seizures (including electrographic‐only seizures) to achieve a lower seizure burden may be associated with improved outcome (expert agreement). Sixth, a trial of pyridoxine may be attempted in neonates presenting with clinical features of vitamin B6‐dependent epilepsy and seizures unresponsive to second‐line ASM (expert agreement). Additional considerations include a standardized pathway for the management of neonatal seizures in each neonatal unit and informing parents/guardians about the diagnosis of seizures and initial treatment options.
Top Cited PapersOpen AccessTreatment of seizures in the neonate: Guidelines and consensus‐based recommendations—Special report from the ILAE Task Force on Neonatal Seizures
Seizures are common in neonates, but there is substantial management variability. The Neonatal Task Force of the International League Against Epilepsy (ILAE) developed evidence‐based recommendations about antiseizure medication (ASM) management in neonates in accordance with ILAE standards. Six priority questions were formulated, a systematic literature review and meta‐analysis were performed, and results were reported following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) 2020 standards. Bias was evaluated using the Cochrane tool and risk of Bias in non‐randomised studies ‐ of interventions (ROBINS‐I), and quality of evidence was evaluated using grading of recommendations, assessment, development and evaluation (GRADE). If insufficient evidence was available, then expert opinion was sought using Delphi consensus methodology. The strength of recommendations was defined according to the ILAE Clinical Practice Guidelines development tool. There were six main recommendations. First, phenobarbital should be the first‐line ASM (evidence‐based recommendation) regardless of etiology (expert agreement), unless channelopathy is likely the cause for seizures (e.g., due to family history), in which case phenytoin or carbamazepine should be used. Second, among neonates with seizures not responding to first‐line ASM, phenytoin, levetiracetam, midazolam, or lidocaine may be used as a second‐line ASM (expert agreement). In neonates with cardiac disorders, levetiracetam may be the preferred second‐line ASM (expert agreement). Third, following cessation of acute provoked seizures without evidence for neonatal‐onset epilepsy, ASMs should be discontinued before discharge home, regardless of magnetic resonance imaging or electroencephalographic findings (expert agreement). Fourth, therapeutic hypothermia may reduce seizure burden in neonates with hypoxic–ischemic encephalopathy (evidence‐based recommendation). Fifth, treating neonatal seizures (including electrographic‐only seizures) to achieve a lower seizure burden may be associated with improved outcome (expert agreement). Sixth, a trial of pyridoxine may be attempted in neonates presenting with clinical features of vitamin B6‐dependent epilepsy and seizures unresponsive to second‐line ASM (expert agreement). Additional considerations include a standardized pathway for the management of neonatal seizures in each neonatal unit and informing parents/guardians about the diagnosis of seizures and initial treatment options.
- 27 July 2023
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 162, 72-80
Sensitivity and specificity of alternative screening methods for systematic reviews using text mining tools
- 27 July 2023
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 162, 72-80
Sensitivity and specificity of alternative screening methods for systematic reviews using text mining tools
- 1 July 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 120, 108006
Risk factors for dementia development, frailty, and mortality in older adults with epilepsy – A population-based analysis
- 1 July 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 120, 108006
Risk factors for dementia development, frailty, and mortality in older adults with epilepsy – A population-based analysis
Primary care electronic medical records can be used to predict risk and identify potentially modifiable factors for early and late death in adult onset epilepsy
Objective To use clinically informed machine learning to derive prediction models for early and late premature death in epilepsy. Methods This was a population‐based primary care observational cohort study. All patients meeting a case definition for incident epilepsy in the Health Improvement Network database for inclusive years 2000‐2012 were included. A modified Delphi process identified 30 potential risk factors. Outcome was early (within 4 years of epilepsy diagnosis) and late (4 years or more from diagnosis) mortality. We used regularized logistic regression, support vector machines, Gaussian naive Bayes, and random forest classifiers to predict outcomes. We assessed model calibration, discrimination, and generalizability using the Brier score, mean area under the receiver operating characteristic curve (AUC) derived from stratified fivefold cross‐validation, plotted calibration curves, and extracted measures of association where possible. Results We identified 10 499 presumed incident cases from 11 194 182 patients. All models performed comparably well following stratified fivefold cross‐validation, with AUCs ranging from 0.73 to 0.81 and from 0.71 to 0.79 for early and late death, respectively. In addition to comorbid disease, social habits (alcoholism odds ratio [OR] for early death = 1.54, 95% confidence interval [CI] = 1.12‐2.11 and OR for late death = 2.62, 95% CI = 1.66‐4.16) and treatment patterns (OR for early death when no antiseizure medication [ASM] was prescribed at baseline = 1.33, 95% CI = 1.07‐1.64 and OR for late death after receipt of enzyme‐inducing ASM at baseline = 1.32, 95% CI = 1.04‐1.66) were significantly associated with increased risk of premature death. Baseline ASM polytherapy (OR = 0.55, 95% CI = 0.36‐0.85) was associated with reduced risk of early death. Significance Clinically informed models using routine electronic medical records can be used to predict early and late mortality in epilepsy, with moderate to high accuracy and evidence of generalizability. Medical, social, and treatment‐related risk factors, such as delayed ASM prescription and baseline prescription of enzyme‐inducing ASMs, were important predictors.
Primary care electronic medical records can be used to predict risk and identify potentially modifiable factors for early and late death in adult onset epilepsy
Objective To use clinically informed machine learning to derive prediction models for early and late premature death in epilepsy. Methods This was a population‐based primary care observational cohort study. All patients meeting a case definition for incident epilepsy in the Health Improvement Network database for inclusive years 2000‐2012 were included. A modified Delphi process identified 30 potential risk factors. Outcome was early (within 4 years of epilepsy diagnosis) and late (4 years or more from diagnosis) mortality. We used regularized logistic regression, support vector machines, Gaussian naive Bayes, and random forest classifiers to predict outcomes. We assessed model calibration, discrimination, and generalizability using the Brier score, mean area under the receiver operating characteristic curve (AUC) derived from stratified fivefold cross‐validation, plotted calibration curves, and extracted measures of association where possible. Results We identified 10 499 presumed incident cases from 11 194 182 patients. All models performed comparably well following stratified fivefold cross‐validation, with AUCs ranging from 0.73 to 0.81 and from 0.71 to 0.79 for early and late death, respectively. In addition to comorbid disease, social habits (alcoholism odds ratio [OR] for early death = 1.54, 95% confidence interval [CI] = 1.12‐2.11 and OR for late death = 2.62, 95% CI = 1.66‐4.16) and treatment patterns (OR for early death when no antiseizure medication [ASM] was prescribed at baseline = 1.33, 95% CI = 1.07‐1.64 and OR for late death after receipt of enzyme‐inducing ASM at baseline = 1.32, 95% CI = 1.04‐1.66) were significantly associated with increased risk of premature death. Baseline ASM polytherapy (OR = 0.55, 95% CI = 0.36‐0.85) was associated with reduced risk of early death. Significance Clinically informed models using routine electronic medical records can be used to predict early and late mortality in epilepsy, with moderate to high accuracy and evidence of generalizability. Medical, social, and treatment‐related risk factors, such as delayed ASM prescription and baseline prescription of enzyme‐inducing ASMs, were important predictors.